The optimal approach to prevent stroke and systemic embolism in patients with advanced
chronic kidney disease (CKD) and atrial fibrillation remains unresolved. We conducted a …

Dabigatran etexilate is an oral direct thrombin inhibitor used in preventing thromboembolism
in patients with atrial fibrillation and several other conditions. Routine dabigatran …

Patients with atrial fibrillation (AF) on long-term direct oral anticoagulants (DOACs) may be
at higher risk of bleeding because of higher anti-Xa or anti-IIa levels. However, there is no …

Currently, anticoagulants would be used to prevent thrombosis. Thrombin is an effector
enzyme for haemostasis and thrombosis. We designed a direct thrombin inhibitor peptide …

Introduction Current guidelines suggest preoperative direct oral anticoagulant levels of< 30-
50ng/ml. However, there is limited evidence to guide this expert consensus. Reviewing …

Background: All evidence regarding benefits and harms of rivaroxaban for stroke prevention
has not been appraised yet. Study Question: What are the comparative effectiveness and …

Whether bleeding should be considered a sufficient sign to justify thorough cancer
surveillance in atrial fibrillation (AF) patients receiving nonvitamin K antagonist oral …

Purpose There are many anticoagulant test indexes available for direct oral anticoagulants
(DOACs), but how to select the appropriate index and the index cutoff values are still …

目的探讨监测活化部分凝血活酶时间(APTT) 对达比加群酯治疗静脉血栓栓塞症(VTE)
病人不良事件发生的影响. 方法回顾性分析2015 年1 月—2017 年12 月我院采用达比加群酯抗 …

Background: A critical appraisal of all pooled evidence regarding novel oral anticoagulants
(NOACs) for stroke prevention regardless of publication status or study design has not been …